Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
What is prostate cancer?
The prostate is a walnut sized gland below the bladder that makes part of the fluid in semen. Prostate cancer starts when cells there grow out of control. It is usually slow growing, often has no symptoms for years, and is most often found through a PSA blood test rather than through anything a man notices. The median age at diagnosis is 68, and it is rare before 40. Black men are about 70 percent more likely to be diagnosed and twice as likely to die from it as white men, a gap researchers are actively studying.
Check our Article about Importance of Diversity in Clinical Trials
What makes prostate cancer different from most cancers is the range. At one end, many low risk cancers can be safely watched with regular PSA tests and scans, an approach called active surveillance, instead of being treated at all. At the other end, cancer that has spread beyond the prostate is treated with hormone therapy, newer androgen receptor blockers, chemotherapy, and, since 2022, a targeted radioactive medicine called Pluvicto that homes in on a protein on prostate cancer cells. Its approval was expanded in March 2025 to earlier use before chemotherapy, and in July 2026 to metastatic hormone sensitive disease.
Types of prostate cancer clinical trials
Trials for advanced and metastatic disease. The largest group. These test new hormone pathway drugs, targeted radiation, PARP inhibitors for men with BRCA and similar mutations, and combinations, usually in men whose cancer has progressed despite hormone therapy (castration resistant) or, increasingly, in men whose cancer still responds to it (hormone sensitive).
Trials for localized disease. Studies of focal treatments that treat only the tumor rather than the whole prostate, such as photodynamic therapy, of shorter radiation courses, and of active surveillance protocols that use MRI and genomic tests to decide who can safely wait.
Screening and detection studies. New imaging like PSMA PET, MRI based screening, better biopsy tools, and blood and urine tests that aim to find aggressive cancers while sparing men with harmless ones. These often enroll men with an elevated PSA who have not been diagnosed.
Genetics studies. About 1 in 10 men with prostate cancer carries an inherited mutation such as BRCA2, which affects treatment choice and family risk. Studies test how to get more men tested and how to help them understand results.
Living with treatment. Hormone therapy raises heart disease and bone loss risk. Studies test how to protect the heart during hormone therapy, manage side effects, and preserve quality of life over the years men now live with this disease.
Registries and biomarker studies. These follow men over time or use blood tests to guide treatment decisions, such as measuring tumor DNA in the blood. No treatment is given, and eligibility is often broad.
Is prostate cancer hereditary?
Partly. Having a father or brother with prostate cancer roughly doubles risk, and about 1 in 10 men with prostate cancer carries an inherited mutation such as BRCA2, which also raises risk in female relatives for breast and ovarian cancer. Most cases, though, occur in men with no family history.
Who can participate in prostate cancer clinical trials?
Prostate cancer trials sort men by a few things you can find in your records. Your disease state: localized, biochemically recurrent (PSA rising after treatment), metastatic hormone sensitive, or metastatic castration resistant, meaning the cancer is growing despite hormone therapy. Your risk group for localized disease, based on PSA, Gleason score, and stage. Your treatment history: many advanced disease trials require that you have already had a specific class of drug, while others want men who have not. And your tumor's features, such as PSMA expression on a PET scan or a BRCA mutation, which specific studies require. Screening studies enroll men with an elevated PSA and no diagnosis, and heart health and quality of life studies often accept any man on hormone therapy. Eligibility always varies by study.
The stages of prostate cancer, and why they matter for trials
Prostate cancer is staged I to IV, but doctors also use risk groups and disease states, because two men at the same stage can need very different care.
Stage I and II (localized). Cancer confined to the prostate. Divided into low, intermediate, and high risk by PSA, Gleason score, and how much of the prostate is involved. Low risk disease is often watched rather than treated. Five year survival approaches 100 percent.
Stage III (locally advanced). Cancer has grown through the prostate capsule or into nearby tissue but not to distant sites. Usually treated with radiation plus hormone therapy, or surgery.
Stage IV (metastatic). Cancer has reached lymph nodes beyond the pelvis, bones, or other organs. Divided into hormone sensitive (still responds to hormone therapy) and castration resistant (growing despite it). Five year survival for distant disease is about 38 percent, and this is where most new drug approvals and trials are concentrated.
Study titles name the disease state, usually as "localized," "metastatic hormone sensitive," or "metastatic castration resistant," and often a marker like "PSMA positive" or "BRCA mutated." Knowing your state and your PSA history tells you at a glance which studies fit.
How to enroll in a prostate cancer clinical trial
Enrolling in a prostate cancer study through our platform takes about 5 minutes. Here is how it works:
Identify your trial. Use the search bar or filters. Prostate cancer study titles name the disease state precisely: "localized," "metastatic castration resistant," "PSMA positive," "BRCA mutated." Match those to your most recent scan and pathology report and most studies rule themselves in or out from the title.
Select your preferred location. Enter your city or state in the filter on the left. Targeted radiation and drug trials run at cancer centers with nuclear medicine and infusion facilities, so distance matters. Screening, genetics, and quality of life studies are often closer to home.
Explore study details. Click "Learn More" for goals, procedures, and eligibility, including which prior treatments are required, whether a PSMA PET scan or genetic test is part of screening, and how visits are scheduled.
Complete the health profile. Click "Get started" to begin the 5-step application. Have three things ready: your current disease state and most recent PSA, your Gleason score or grade group from the biopsy, and the list of treatments you have had, including hormone therapy. Those answers decide eligibility for nearly every prostate cancer study.
Submit the application. A clinical trial coordinator reviews it and contacts you about whether you may qualify. Nothing is decided until you have gone through informed consent, and participation is voluntary at every step. Your urologist or oncologist stays involved throughout.